Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00071084 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.
A Phase 2 study, sponsored by Genmab.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT00071084 is a Phase 2 study that has completed, run by Genmab. The registered enrollment target is 22 participants.
The verdict
NCT00071084, a Phase 2 study, has completed, sponsored by Genmab.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this trial is to determine the effect of HuMax-CD4, as a treatment for advanced stage (late stage) cutaneous T-cell lymphoma (CTCL). Almost all participants who are affected by late stage CTCL have many cancerous cells which bear a receptor called CD4. HuMax-CD4 is an investigational drug directed against this receptor. There is no placebo in this trial; all participants will be treated with HuMax-CD4. The response rates, duration of responses, relief of symptoms, and safety profile of HuMax-CD4 will be evaluated during this trial.
Interventions
- DRUG HuMax-CD4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2003-05-27 |
| Est. Completion | 2004-06-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00071084
The ClinicalTrials.gov registry entry for NCT00071084 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genmab, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HuMax-CD4 is the first listed.
NCT00071084 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00071084 about?
NCT00071084 is a clinical study titled "Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.". The purpose of this trial is to determine the effect of HuMax-CD4, as a treatment for advanced stage (late stage) cutaneous T-cell lymphoma (CTCL). Almost all participants who are affected by late stage CTCL have many cancerous cells which bear a receptor called CD4. HuMax-CD4 is an investigational ...
What is the current status of trial NCT00071084?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2003-05-27. Estimated completion is 2004-06-29.
What interventions are being tested in trial NCT00071084?
The interventions under investigation include: HuMax-CD4 (DRUG).
Who is sponsoring clinical trial NCT00071084?
This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.